NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Yes the MHRA (like FDA/EMA) requires full GMP validation before granting approval. That’s true for any manufacturer. But the idea that “MHRA was waiting for Advent to be acquired” is way off base. Regulators don’t care whether the facility is owned by NWBO, Advent, CRL, or whoever they care that the site is licensed, validated, and can produce a consistent product. Advent already had the MHRA licenses in its own name, so that box was checked long ago.
Owning Advent doesn’t magically make GMP compliance easier or speed approval. It just cleans up corporate governance and removes related-party optics — something Big Pharma cares about when evaluating M&A.

And switching to Flaskworks is a separate compatibility exercise down the line. Regulators will demand a full validation package no matter who owns the site. The acquisition doesn’t change that either. Folding Advent into NWBO is about optics for suitors and corporate hygiene, not because MHRA couldn’t approve without it. Approval depends on the data, the validated process, and the existing licenses — all of which Advent already held.